Clinical Trial Recruitment Turns to Laboratory Data, but Precision Medicine’s Bottlenecks Are Not Only About New Drugs

New drug R&D is often imagined as a race involving molecules, targets, and clinical endpoints, but the point where many trials truly get stuck is often before the “right patients” are found. A recent Fierce Biotech article on data-driven diagnostic laboratory services focuses on this less publicly discussed link: as clinical trials place increasing emphasis on genetic mutations, protein expression, immune characteristics, or disease subtypes, laboratory data are no longer just test results, but may become critical infrastructure determining whether a trial can start and whether enrollment can be completed on time.

The core concept behind this type of service is not mysterious. Diagnostic laboratories have long handled large volumes of specimens, testing workflows, and clinical reports. If existing testing data can be organized under compliant conditions, there may be an opportunity to help pharmaceutical companies or research teams estimate the real-world distribution of specific biomarkers and determine which regions, medical institutions, or patient groups are more likely to meet inclusion criteria. For cancer, rare disease, or immune-related trials that require precise subtyping, this could reduce blind site activation and inefficient screening.

But “data-driven” cannot be simplified into a universal answer. The problems facing clinical trial recruitment often involve testing quality, the completeness of medical records, population representativeness, physicians’ willingness to refer, and whether patients are willing to participate in research. Laboratory data can narrow the search range, but they cannot guarantee that every data point is sufficient to determine eligibility; the timing of testing, testing methods, report formats, and changes in clinical status may all affect whether data can be safely repurposed for trial planning.

More sensitive still are privacy and governance. If diagnostic data are used to support clinical research, de-identification, patient consent, the boundaries of data use, and rules for cross-institutional sharing must all be clearly defined. Even if data are used for feasibility assessment rather than direct recruitment, researchers still need to avoid allowing algorithms or databases to exclude specific groups from trials, especially in disease areas where access to care is already unequal.

### Background Context

In recent years, clinical trials have become more difficult. On one hand, new drug development increasingly relies on precision biology, dividing what appears to be the same disease into smaller molecular subgroups; on the other hand, this also makes eligible patients more dispersed and harder to identify. If trials cannot enroll effectively, this not only slows R&D timelines, but may also make early efficacy signals blurrier because of insufficient sample sizes.

As a result, the boundaries between diagnostic companies and clinical research services are becoming more fluid. If laboratories can connect testing capabilities, data analysis, and trial operations, they may indeed make research design more closely reflect the distribution of real patients; however, currently available public information is quite limited and still insufficient to judge the actual effectiveness of specific services across different diseases and different healthcare systems. What will truly persuade the clinical community will still be transparent methods, auditable validation results, and evidence that patient rights and interests are placed at the center of the process.